Background: Whole-body electromyostimulation (WB-EMS) was never previously applied to Parkinson's disease (PD) patients. This randomized controlled study aimed to find the most effective and safe WB-EMS training protocol for this population. Methods: Twenty-four subjects (age: 72.13 6.20 years), were randomly assigned to three groups: a high-frequency WB-EMS strength training group (HFG) (rectangular stimulation at 85 Hz, 350 ms, 4 s stimulation/4 s rest), a low-frequency WBEMS aerobic training group (LFG) (rectangular stimulation 7 Hz, 350 ms, with a continuous pulse duration), and an inactive control group (CG). Participants of thetwo experimental groups underwent 24 controlled WB-EMS training sessions, with a duration of 20 min each, during 12-week intervention. Serum growth factors (BDNF, FGF-21, NGF and proNGF), a-synuclein, physical performance and Parkinson's Disease Fatigue Scale (PFS-16) responses were analyzed to evaluate the pre-post variation and differences among groups.Results: Significant interactions of TimeGroups were detected for BDNF (Time x Groups p = 0.024; Time x CG, b = -628, IC95% = -1,082/-174, p = 0.008), FGF-21 (Timex Groups p = 0.009; Time x LFG b = 1,346, IC95% = 423/2268,p = 0.005), and a-synuclein (Time x Groups p = 0.019; Time x LFG b = -1,572, IC95% = -2,952/-192, p = 0.026). Post hoc analyses and comparisons of 1S (post-pre), performed independently for each group, showed that LFG increased serum BDNF levels (C 203 pg/ml) and decreased a-synuclein levels (-1,703 pg/ml), while HFG showed the opposite effects (BDNF: ?500 pg/ml; a-synuclein: C 1,413 pg/ml).CG showed a significant BDNF reduction over time. Both LFG and HFG showed significant improvements in several physical performance outcomes and the LFG showed better results than HFG. Concerning PFS-16, significant differences over time (b = -0.4, IC95% = -0.8/-0.0, p = 0.046) and among groups (among all groups p < 0.001) were found, and the LFG exhibited better results than the HFG (b = -1.0, IC95% = -1.3/-0.7, p < 0.001), and CG (b = -1.7, IC95% = -2.0/-1.4, p < 0.001) with this last one that worsened over time.Conclusion: LFG training was the best choice for improving or maintaining physical performance, fatigue perception and variation in serum biomarkers.Clinical trial registration: https://www.clinicaltrials.gov/ct2/show/NCT04878679, identifier NCT04878679.

Whole body-electromyostimulation effects on serum biomarkers, physical performances and fatigue in Parkinson's patients: A randomized controlled trial

Luigi Manni;Marzia Soligo;
2023

Abstract

Background: Whole-body electromyostimulation (WB-EMS) was never previously applied to Parkinson's disease (PD) patients. This randomized controlled study aimed to find the most effective and safe WB-EMS training protocol for this population. Methods: Twenty-four subjects (age: 72.13 6.20 years), were randomly assigned to three groups: a high-frequency WB-EMS strength training group (HFG) (rectangular stimulation at 85 Hz, 350 ms, 4 s stimulation/4 s rest), a low-frequency WBEMS aerobic training group (LFG) (rectangular stimulation 7 Hz, 350 ms, with a continuous pulse duration), and an inactive control group (CG). Participants of thetwo experimental groups underwent 24 controlled WB-EMS training sessions, with a duration of 20 min each, during 12-week intervention. Serum growth factors (BDNF, FGF-21, NGF and proNGF), a-synuclein, physical performance and Parkinson's Disease Fatigue Scale (PFS-16) responses were analyzed to evaluate the pre-post variation and differences among groups.Results: Significant interactions of TimeGroups were detected for BDNF (Time x Groups p = 0.024; Time x CG, b = -628, IC95% = -1,082/-174, p = 0.008), FGF-21 (Timex Groups p = 0.009; Time x LFG b = 1,346, IC95% = 423/2268,p = 0.005), and a-synuclein (Time x Groups p = 0.019; Time x LFG b = -1,572, IC95% = -2,952/-192, p = 0.026). Post hoc analyses and comparisons of 1S (post-pre), performed independently for each group, showed that LFG increased serum BDNF levels (C 203 pg/ml) and decreased a-synuclein levels (-1,703 pg/ml), while HFG showed the opposite effects (BDNF: ?500 pg/ml; a-synuclein: C 1,413 pg/ml).CG showed a significant BDNF reduction over time. Both LFG and HFG showed significant improvements in several physical performance outcomes and the LFG showed better results than HFG. Concerning PFS-16, significant differences over time (b = -0.4, IC95% = -0.8/-0.0, p = 0.046) and among groups (among all groups p < 0.001) were found, and the LFG exhibited better results than the HFG (b = -1.0, IC95% = -1.3/-0.7, p < 0.001), and CG (b = -1.7, IC95% = -2.0/-1.4, p < 0.001) with this last one that worsened over time.Conclusion: LFG training was the best choice for improving or maintaining physical performance, fatigue perception and variation in serum biomarkers.Clinical trial registration: https://www.clinicaltrials.gov/ct2/show/NCT04878679, identifier NCT04878679.
2023
FARMACOLOGIA TRASLAZIONALE - IFT
Parkinson's disease
neurotrophic factors
physical activity
functional capacity
muscle stimulation
File in questo prodotto:
File Dimensione Formato  
prod_477717-doc_195513.pdf

accesso aperto

Descrizione: Manoscritto
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 4.01 MB
Formato Adobe PDF
4.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/458633
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact